Gonococcal ophthalmia neonatorum (GON) is a neonatal conjunctival infection transmitted intrapartum from mothers infected with Neisseria gonorrhoeae to their newborns. Although GON is rare in the United States, with 0.4 cases or fewer per 100 000 live births per year during 2013-2017, 1 prevention remains important because of high risk of corneal perforation and blindness, which can develop within 24 hours after delivery. 2 Preventive strategies for GON include screening for and treatment of gonorrhea in pregnant women and ocular prophylaxis in newborns, which is mandated in most states. Since 1996, the US Preventive Services Task Force (USPSTF) has maintained an "A" recommendation for prophylactic ocular topical medication for all newborns for the prevention of GON, based on good evidence that blindness due to GON has become rare in the United States since the implementation of universal preventive medication of infants. This brief evidence update was used by the USPSTF to update its 2011 "A" recommendation. 3 Methods | Because ocular prophylaxis for GON represents a long-established standard of practice, the USPSTF commissioned a targeted review using a reaffirmation updating process to identify "new and substantial evidence sufficient enough to change the prior recommendation." 4 As such, only the interval evidence since the previous systematic review was evaluated. An analytic framework and 2 key questions guided the evidence update ( Figure) . Detailed methods, including the search strategy, inclusion and exclusion criteria, criteria for critical appraisal, and a list of excluded studies, are available in the full evidence report at http://www. uspreventiveservicestaskforce.org /Page/Document/ UpdateSummaryFinal/ocular-prophylaxis-for-gonococcalophthalmia-neonatorum-preventive-medication1.
Results | PubMed and the Cochrane Central Register of Controlled Trials were searched from January 1, 2008, to January 16, 2018. Two reviewers independently reviewed 282 unique citations and 6 full-text articles.
No new publications meeting eligibility criteria were identified.
Discussion | This systematic review yielded no relevant new studies since the previous USPSTF recommendation addressing the effectiveness and harms of GON prophylaxis (Table) . 3 The foundational evidence for prior USPSTF recommendations largely consisted of observational studies from subSaharan Africa conducted in the 1980s and 1990s. Given the low prevalence of maternal gonorrhea in developed countries, any contemporary study conducted in a developed country would be underpowered. Comparative effectiveness studies, including one conducted in the United States, have found no statistically significant differences in efficacy for GON prevention with different agents, including silver What is the effectiveness of ocular prophylaxis for the prevention of gonococcal ophthalmia neonatorum and associated blindness?
What are the harms of ocular prophylaxis for the prevention of gonococcal ophthalmia neonatorum? 2
Newborns
Reduced gonococcal ophthalmia neonatorum and associated blindness nitrate, erythromycin, tetracycline, and povidone iodine, although conclusions are limited by low power.
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Although the USPSTF and other bodies recommend universal GON prophylaxis based on the foundational evidence, others, such as the Canadian Pediatric Society, have questioned the current applicability of such evidence because the universal prenatal screening and treatment of sexually transmitted infections introduced in the 1970s is considered the most effective preventive strategy and the standard of care. It is possible that state-mandated ocular prophylaxis may be less warranted in settings with comprehensive access to prenatal care, including screening pregnant women for gonorrhea and addressing infections before birth. However, not all US women receive prenatal care. In the United States, where risk-based prenatal gonorrhea screening is recommended and ocular prophylaxis is the standard of care, the individual contribution of each method for preventing GON is unknown.
The ideal candidate agent for prophylaxis would be effective against GON but with low risk of antibiotic resistance, not cause chemical conjunctivitis, be inexpensive in single-dose vials, and be approved by the US Food and Drug Administration and available in the United States. Currently, erythromycin fulfills most of these criteria, but some concerns remain about potential antibiotic resistance 6 and data on the incidence of chemical conjunctivitis with erythromycin agents are scarce. 
COMMENT & RESPONSE Precision Medicine vs Preventive Medicine
To the Editor Dr Psaty and colleagues 1 compared precision medicine and preventive medicine as 2 distinct models in medicine. They posited that precision medicine is deterministic, often with a gene-centric approach, while preventive medicine is probabilistic and applies to common conditions such as hypertension and hyperlipidemia. The 2 models are complementary and not competitive. Emerging scientific evidence will guide physicians toward preventive and curative interventions that can work best at the population or individual levels. As envisioned by the All of Us research program, 2 precision medicine encompasses both treatment and prevention and is more than genetics: "Precision medicine takes into account individual differences in lifestyle, environment, and biology." Furthermore, precision does not necessarily imply biologic determinism. Most human diseases are due to complex gene-environment interactions that can lead only to probabilistic approaches to prevention. The term precision prevention first appeared in the literature in 2014. 3 According to Bíró et al, 4 "precision prevention involves use of biologic, behavioral, socioeconomic and epidemiologic data to devise and implement strategies tailored to reducing cancer incidence and mortality in a specific individual or group of individuals." Such definitions emphasize that precision can go beyond genomic-based screening to integrate environmental and social determinants of health. Currently available population cancer prevention and earlydetection approaches can reduce a large proportion of the cancer burden, but even if fully implemented, they cannot eliminate cancer. Cardiovascular disease also illustrates precision prevention. Familial hypercholesterolemia 5 is a common genetic disorder that significantly increases the risk of premature death due to cardiovascular disease. Familial hypercholesterolemia is underdiagnosed and undertreated. More precision in finding people with familial hypercholesterolemia and their at-risk relatives is needed. Beyond genetics, blood pressure reduction in the population to prevent cardiovascular events can benefit from targeting subpopulations at high risk based on sociodemographic or other factors.
